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Introduction: Spasm of the human internal mammary artery (HIMA) 
is a rare but life-threatening complication after coronary artery 
bypass grafting (CABG). The reversal of this vasospasm is often chal-
lenging, and the most effective therapy is not well defined. The pre-
sent study was aimed to investigate vasorelaxant effect of nicorandil, 
K+ channel opener, on the HIMA and to define the role of different 
K+ channel subtypes in nicorandil action on this blood vessel.
Patients (or Materials) and Methods: Discarded segments of HIMA 
were collected from patients undergoing CABG and studied in organ 
baths. HIMA rings were precontracted with phenylephrine (10 µM) 
followed by cumulatively adding increasing doses of nicorandil. The 
endothelium was removed mechanically.
Results: Nicorandil (0.001 µM–300 µM) induced a concentration-
dependent relaxation of HIMA rings precontracted by phenylephrine. 
Glibenclamide (10 μ M), a highly selective blocker of ATP-sensitive 
K+ (KATP) channels, partially inhibited relaxation of HIMA induced 
by nicorandil. Tetraethylammonium (TEA, 1 mM), a nonselective 
blocker of Ca2+-activated K+ (KCa) channels, as well as iberiotoxin 
(100 nM), a most selective blocker of large-conductance KCa (BKCa) 
channels, partly antagonized relaxation of HIMA. A nonselective 
blocker of voltage-gated K+ (KV) channels, 4-aminopyridine (4-AP, 
0.5 mM), as well as margatoxin (10 nM), a potent inhibitor of KV1.3 
channels, did not significantly modify the nicorandil-induced relaxa-
tion of HIMA.
Conclusion: The results from our study demonstrate that, in HIMA, 
nicorandil has a potent vasorelaxant effect which is endothelium-
independent. It seems that mechanism of this relaxation includes 
KATP and 4-AP-sensitive K+ channels located in the smooth muscle 
of HIMA.
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Introduction: Thrombosis is 1 of the major causes of death world-
wide. Atherothrombotic diseases such as myocardial or cerebral 
infarction are serious consequences of the thrombus formed in 
blood vessels. Nattokinase is new fibrinolytic enzyme with a 
molecular weight of 27 728 Da that cleaves directly cross-linked 
fibrin in vitro. In this study, we investigated the effect of nat-
tokinase supplementation on thrombus formation using different 
animal models.
Patients (or Materials) and Methods: To study the fibrinolytic activ-
ity, in vitro clot dissolution assay was done in which clot was formed 
in helix and then kept in contact with different concentrations of 
nattokinase and streptokinase (standard drug) and its clot dissolution 
property was studied. Further it was studied for its antithrombotic 
activity in venous thrombosis. Rats were pretreated orally for 7 days 
with Nattokinase (100 and 200 mg/kg). One hour after the last dose, 
stasis was developed in the inferior vena cava in rats, and its activity 
was intensified with the help of ferric chloride. It was also studied 
for its antithrombotic activity in arterial thrombosis using arterio-
venous shunt-induced thrombosis in rats. In this rats were pretreated 
orally for 7 days with Nattokinase (100 and 200 mg/kg) and on last 
day 1 hour after last dose thrombosis was induced by arterio-venous 
shunt. In both the above studies, % inhibition of thrombus forma-
tion was calculated. Because hemorrhage is an important side effect 
of antithrombotic and thrombolytic therapies, the drug was studied 
for its effect on hemorrhage using rat tail transaction method. Here, 
effect of 7 days pretreatment of 2 doses of nattokinase (100 and 200 
mg/kg) on hemorrhage was studied.
Results: In in vitro clot dissolution assay, there was significant and 
dose-dependent clot dissolution with different concentration of nat-
tokinase. Maximum activity, 94.43 % inhibition, was seen in 3000ug/
mL concentration which was comparable with 1000 IU of strepto-
kinase. In venous thrombosis model, it showed significant and dose-
dependent inhibition of thrombus formation as indicated by decrease 
in weight of thrombus. Antithrombotic potential of nattokinase at the 
highest dose (200 mg/kg) showed 45.431% inhibition with respect to 
saline control group. In arterio-venous shunt ,it showed no significant 
inhibition of thrombus formation on thrombogenic surface. In the 
rat tail transaction model, both the doses of nattokinase (100 and 
200 mg/kg) has significantly increased the bleeding time with not 
much effect on blood loss. Also, the platelet MDA was significantly 
decreased in both groups treated with 100 and 200 mg/kg of nat-
tokinase.
Conclusion: The results of various in vitro and in vivo models stud-
ied indicate that nattokinase has a good potential as an antithrom-
botic and fibrinolytic agent.
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Introduction: High blood pressure (HBP) is a disease with high 
morbidity and mortality worldwide and is considered 1 of the main 
etiologic factors of multiple cardiac pathologies like cardiac hyper-
trophy, myocardial infarction, among others. One of the regulatory 
mechanisms of blood pressure is the renin angiotensin system (RAS), 
so much so that the first-line drugs in the treatment of hyperten-
sion are directed to some of the components of the RAS. However, 
these treatments frequently lead to the development of changes in 
morphology and physiology characterized by vascular complications 
.It is therefore necessary to consider adjuvant therapies to improve 
the outlook and quality of life of patients with HBP. A therapy that 
has been shown clinically to improve the condition of patients with 
HBP is hyperbaric oxygenation (HBO), which consists in subject-
ing a subject at a pressure > 2 atmospheres absolute with an 100% 
oxygen. This therapy has been shown to improve vascular smooth 
muscle relaxation, although the mechanism of action has not yet 
been specified.
